Replies to post #50942 on AmeraMex International Inc. (AMMX)

[NASDAQ2020]

Cash Flow Positive for years $40 Million revenues and growing rapidly: All this in next year or two:

X 1. Full ownership of Adderall IR $335 Million
X 2. In house marketing and distribution: Kirkov
X 3. Generic OxyContin- FIRST TO FILE Aug 17, 2023 $720 Million
—4. Full ownership of Adderall XR $ 1.56 Billion
—5. Generic Concerta- $1.2 BILLION
—6. Generic Vyvanse- $5.3 BILLION
X 7. Vigabatrin - approved Commercialized by Pyros $233 Million
—8. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
—9. Patented Unique ADF (w/o naltrexone)-- NDA
—10. Mikah ANDA
—11. Undisclosed
—12. Antimetabolite ANDA- Methotrexate -$600 Million
—13. Undisclosed Antimetabolite ANDA- $42 Million
—14. Prasco/Burel Adderall agreement
—15. Dexcel partnership approval by Israeli health for European distribution